{
  "id": 19823279,
  "title": "Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties",
  "url": "https://urgent.news/2026/11/13/novo-submits-sickle-cell-drug-flagship-gates-foundation-deepen-ties",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-13T14:36:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/novo-etavopivat-flagship-gates-ascidian-immuneering-neurosterix/874120/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Novo views the medicine, acquired in a billion-dollar deal, as a future blockbuster. Meanwhile, a pair of startups forged an RNA editing pact and Astellas lined up two new trials in pancreatic cancer.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}